XORTX Therapeutics Files April 2025 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Apr 18, 2025 · CIK: 1729214
Sentiment: neutral
Topics: reporting, 6-K, regulatory
TL;DR
XORTX filed its April 6-K, confirming 20-F annual reports. CEO Davidoff signed off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on April 18, 2025, reporting for the month of April 2025. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. Allen Davidoff, Chief Executive Officer, signed the report on April 17, 2025.
Why It Matters
This filing provides an update on XORTX Therapeutics' reporting status as a foreign private issuer, which is relevant for investors tracking their regulatory compliance and financial reporting schedule.
Risk Assessment
Risk Level: low — This is a routine reporting form (6-K) that does not contain new material financial or operational information, but rather confirms reporting status.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- April 17, 2025 (date) — Report signing date
- April 2025 (date) — Reporting period
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of April 2025.
Which annual report form does XORTX Therapeutics Inc. file?
XORTX Therapeutics Inc. files annual reports under cover of Form 20-F.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the report.
On what date was this Form 6-K report signed?
The report was signed on April 17, 2025.
What is the Commission File Number for XORTX Therapeutics Inc.?
The Commission File Number for XORTX Therapeutics Inc. is 001-40858.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 18, 2025 by Allen Davidoff regarding XORTX Therapeutics Inc. (XRTX).